GlassScriptPhysician profile
Heather Burzinski Sullivan
NPI 1750683967
$1,445.59
in general payments reported to CMS, 2019-2025
13 companies · $998 in 2025
The $998 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.57 · 2022: $55.16 · 2023: $18.05 · 2024: $359 · 2025: $998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,374.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $303.98 | 2025 | Invega Sustenna |
| Glaxosmithkline, LLC. | $256.60 | 2023-2024 | Arexvy, Pediarix, Shingrix |
| Neurocrine Biosciences, INC. | $194.11 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $131.21 | 2025 | Uzedy, Austedo Xr |
| Alkermes, INC. | $124.99 | 2025 | Aristada, Aristada Initio |
| Pfizer INC. | $120.25 | 2024 | |
| Si-Bone, INC. | $116.47 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $69.33 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $43.16 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $42.50 | 2025 | Rexulti |
| Janssen Biotech, INC. | $15.57 | 2021 | |
| Phadia US INC. | $15.42 | 2025 | Immunocap |
| Dexcom, INC. | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.